NCT05059158Recruiting
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
Amyloid-β Clearance Mechanisms: A Multi-modal Study on Lymphatic, Glymphatic and Blood-brain-barrier Function in Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 4 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The focus of this study is to examine the protein-plaque clearance (Aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. In order to achieve this aim the investigators intend to study participants with a Subjective Cognitive Decline, Mild Cognitive Impairment and a mild Alzheimer's disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 15 Jul 2021
- Start date
- Jun 2021
- Primary completion date
- Sept 2025
- Lead sponsor
- Ludwig-Maximilians - University of Munich
- Diseases
- Alzheimer disease
- NCT number
- NCT05059158
What you commit to
- Study type: Observational
- Planned participants: 60
- From Jun 2021 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current alcohol, drug or medication abuse
- History of severe traumatic brain injury within 3 months prior to inclusion
- Unresolved malignancies within two years prior to inclusion
Other illness
- Other severe mental disorder, e.g. schizophrenia or bipolar affective disorder
- Severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus
- Severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension
- Electronic implants (e.g. cardiac pacemaker) or other MRI contraindication
- Severe current infections or other chronic or systemic disorders
Lab values
- Renal failure \> stage 3 (GFR \< 30 mL/min)
Other
- Unable to give informed consent or has a legal guardian
- Clinically relevant depression
- Acute suicidality
- Structural lesions of the basal ganglia or brain stem
- Pregnancy
- Other circumstances which preclude participation based on the investigator's judgement
Who the study is looking for
- Diagnosis of amnestic MCI or AD dementia or clinical normal
- Able to provide written informed consent
- Unchanged pharmacotherapy within 4 days prior to the study specific assessments
- Fluent in German
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums Coordinator of this site? Confirm its status | München | Germany | Recruiting |
Related publications
- Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer's disease.Aging Clin Exp Res · 2026 · PMID 42348024
This page is information, not medical advice. Discuss any trial with your doctor.